

# 3<sup>rd</sup> International Symposium on Novel Anticancer Agents for Practicing Oncologists

Madrid June 10, 2015

15:00 Welcome and Introduction.

*Organizing Committee: Emiliano Calvo (START Madrid CIOCC), Victor Moreno (START Madrid FJD) and Jesús García Foncillas, (FJD).*

15:15: Gastrointestinal Cancer: novel antiangiogenics.

**Moderator: Antonio Cubillo, Centro Integral Oncológico Clara Campal. Madrid, Spain.**

**15:15-15:45: New options for the treatment of metastatic gastric cancer: Ramucirumab.**

*Presenter: Josep Tabernero, Hospital Vall d'Hebron, Barcelona, Spain.*

**15:45-16: 15: Aflibercept for the treatment of metastatic colorectal cancer.**

*Presenter: Eric Van Cutsem, University Hospital Gasthuisberg Leuven, Belgium.*

16:15 Melanoma: therapy with anti PD-1 agents.

**Moderator: Victoria Casado, Hospital Fundación Jiménez Díaz, Madrid, Spain.**

**16:15-16:45: Pembrolizumab for the treatment of metastatic melanoma.**

*Presenter: Caroline Robert, Institute Gustave Roussy, Villejuif, France.*

**16:45-17:15: Nivolumab for the treatment of metastatic melanoma.**

*Presenter: Salvador Martín Algarra, Clínica Universitaria de Navarra. Spain.*

*Coffe break: 17:15 – 17:45*

17:45: Gynecological tumors: new targeted therapy for advanced disease.

**Moderator: Cristóbal Belda, Centro Integral Oncológico Clara Campal. Madrid, Spain.**

**17:45-18:15: Current management of BRCA mutant ovarian cancer: Olaparib for the treatment of BRCA metastatic ovarian cancer.**

*Presenter: Antonio González, M.D. Anderson Cancer Center, Madrid.*

**18:15-18:45: Palbociclib for the treatment of HR+ metastatic breast cancer.**

*Presenter: Miguel Martín, Hospital Gregorio Marañón, Madrid. Spain.*

## 18:45: Lung cancer

**Moderator: Manuel Dómine, Hospital Fundación Jiménez Díaz, Madrid, Spain.**

**18:45-19:15: Current management of ALK positive NSCLC after progression to Crizotinib.**

*Presenter: Rafael Rosell, Hospital Germans Trias i Pujol. Badalona , Spain.*

**19:15-19:45: Management of EGFR mutated lung cancer after progression to EGFR inhibition.**

*Presenter: Luis Paz-Ares, Hospital 12 de Octubre, Madrid*